Royalty Research Development from 2010 to 2026

RPRX Stock  USD 40.41  0.33  0.81%   
Royalty Pharma Research Development yearly trend continues to be fairly stable with very little volatility. Research Development will likely drop to about 2.2 M in 2026. During the period from 2010 to 2026, Royalty Pharma Research Development regression line of annual values had r-squared of  0.01 and arithmetic mean of  77,730,353. View All Fundamentals
 
Research Development  
First Reported
2000-03-31
Previous Quarter
300.5 M
Current Value
50.5 M
Quarterly Volatility
35.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 272.3 M, Total Revenue of 2.7 B or Research Development of 2.2 M, as well as many indicators such as Price To Sales Ratio of 10.18, Dividend Yield of 0.0363 or PTB Ratio of 1.79. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Build AI portfolio with Royalty Stock
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Research Development Growth Pattern

Below is the plot of the Research Development of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Very volatile
   Research Development   
       Timeline  

Royalty Research Development Regression Statistics

Arithmetic Mean77,730,353
Geometric Mean28,505,734
Coefficient Of Variation131.25
Mean Deviation72,469,474
Median27,107,000
Standard Deviation102,017,583
Sample Variance10407.6T
Range390.6M
R-Value0.09
Mean Square Error11008.3T
R-Squared0.01
Significance0.73
Slope1,850,586
Total Sum of Squares166521.4T

Royalty Research Development History

20262.2 M
20252.3 M
2024M
202352 M
2022177.1 M
2021200.1 M
202026.3 M

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development2.3 M2.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.